130,894 Shares in Humacyte, Inc. (NASDAQ:HUMA) Purchased by Thrivent Financial for Lutherans

Thrivent Financial for Lutherans bought a new position in shares of Humacyte, Inc. (NASDAQ:HUMA - Free Report) in the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm bought 130,894 shares of the company's stock, valued at approximately $712,000. Thrivent Financial for Lutherans owned 0.11% of Humacyte at the end of the most recent reporting period.

A number of other hedge funds have also added to or reduced their stakes in HUMA. Millennium Management LLC grew its position in shares of Humacyte by 504.3% during the 2nd quarter. Millennium Management LLC now owns 1,599,307 shares of the company's stock worth $7,677,000 after buying an additional 1,334,641 shares during the period. Vanguard Group Inc. increased its stake in Humacyte by 28.7% in the first quarter. Vanguard Group Inc. now owns 4,019,681 shares of the company's stock valued at $12,501,000 after purchasing an additional 896,415 shares in the last quarter. Renaissance Technologies LLC raised its holdings in shares of Humacyte by 693.0% during the second quarter. Renaissance Technologies LLC now owns 600,300 shares of the company's stock valued at $2,881,000 after purchasing an additional 524,600 shares during the period. Marshall Wace LLP raised its holdings in shares of Humacyte by 3,301.5% during the second quarter. Marshall Wace LLP now owns 463,662 shares of the company's stock valued at $2,226,000 after purchasing an additional 450,031 shares during the period. Finally, Deerfield Management Company L.P. Series C bought a new position in shares of Humacyte during the 2nd quarter worth about $1,550,000. 44.71% of the stock is currently owned by institutional investors.

Insider Buying and Selling at Humacyte

In related news, Director Brady W. Dougan sold 427,459 shares of the business's stock in a transaction on Tuesday, November 19th. The stock was sold at an average price of $4.34, for a total transaction of $1,855,172.06. Following the sale, the director now directly owns 1,992,253 shares in the company, valued at approximately $8,646,378.02. The trade was a 17.67 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Kathleen Sebelius sold 5,182 shares of the business's stock in a transaction on Tuesday, September 10th. The shares were sold at an average price of $5.40, for a total value of $27,982.80. Following the sale, the director now owns 40,276 shares in the company, valued at approximately $217,490.40. The trade was a 11.40 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 1,662,886 shares of company stock worth $7,489,538 over the last ninety days. 11.20% of the stock is currently owned by company insiders.

Humacyte Stock Performance

Humacyte stock traded up $0.16 during mid-day trading on Wednesday, reaching $4.41. 1,317,985 shares of the company's stock were exchanged, compared to its average volume of 2,416,528. The business's fifty day simple moving average is $5.17 and its 200 day simple moving average is $6.13. The firm has a market capitalization of $555.04 million, a PE ratio of -3.17 and a beta of 1.38. Humacyte, Inc. has a one year low of $2.45 and a one year high of $9.97. The company has a quick ratio of 1.10, a current ratio of 1.10 and a debt-to-equity ratio of 0.61.

Wall Street Analyst Weigh In

A number of research analysts recently weighed in on HUMA shares. EF Hutton Acquisition Co. I raised Humacyte to a "strong-buy" rating in a research note on Monday, September 9th. Benchmark reissued a "buy" rating and issued a $15.00 price objective on shares of Humacyte in a research note on Thursday, October 10th. Cantor Fitzgerald reaffirmed an "overweight" rating and set a $13.00 target price on shares of Humacyte in a research report on Friday, September 20th. BTIG Research reaffirmed a "buy" rating and set a $10.00 target price on shares of Humacyte in a research report on Friday, October 18th. Finally, D. Boral Capital reaffirmed a "buy" rating and set a $25.00 target price on shares of Humacyte in a research report on Thursday, November 21st. One research analyst has rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat, the company presently has a consensus rating of "Buy" and a consensus price target of $13.00.

Humacyte Company Profile

Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.